Which of the direct acting anti-viral agents is the better drug in terms of efficacy, cost and safety, Boceprevir or Telaprevir?

Year 2019, , 88 - 95, 30.05.2019

Mark Aziz

https://doi.org/10.17546/msd.501220

Abstract

Objective:  Hepatitis C virus can cause chronic hepatitis with 20-30% of those infected are developing liver cirrhosis and some developing hepatocellular carcinoma. It is a global health problem with 130-170 million people infected worldwide. The current treatment uses pegylated interferon and Ribavirin. As of 2011, two new drugs have been approved in the U.S.A and Europe, the protease inhibitors Boceprevir and Telaprevir. The aim of this structured review is to investigate which of these two new drugs is better in terms of efficacy, safety and cost. A literature search was conducted using various primary and secondary sources. A database search was conducted to find three journals for critical review. Conclusion: The articles showed that the two drugs are equally effective and more effective than standard therapy. Boceprevir is potentially significantly cheaper. Boceprevir may also have a slightly better adverse effects profile. However, it is evident that direct clinical trials comparing the two drugs are required.

Keywords

HCV, Bocepravir, Telaprevir, Review

References

• 1. Houghton M. Discovery of the hepatitis C virus. Liver international : official journal of the International Association for the Study of the Liver. [Historical Article Review]. 2009 Jan;29 Suppl 1:82-8.
• 2. Steven R. Recent advances in the molecular biology of hepatitis C virus. Journal of Molecular Biology. 2001;313(3):451-64.
• 3. Alter H. Discovery of non-A, non-B hepatitis and identification of its etiology. American Journal of Medicine. 1999;107(6 SUPPL. 2):16-20.
• 4. Houghton M. The long and winding road leading to the identification of the hepatitis C virus. Journal of hepatology. 2009;51(5):939-48.
• 5. Joyce MA, Tyrrell DLJ. The cell biology of hepatitis C virus. Microbes and Infection. 2010;12(4):263-71.
• 6. Tang H, Grisé H. Cellular and molecular biology of HCV infection and hepatitis. Clinical Science. 2009;117(2):49-65.
• 7. Von Hahn T, Steinmann E, Ciesek S, Pietschmann T. Know your enemy: Translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology. 2010;4(1):63-79.
• 8. Greenwood. D SR, Peutherer. J, Barer. M. Medical Microbiology a guide to microbial infections: pathogenesis, immunity, laboratory diagnosis and control. Edinburgh ; Churchill Livingstone/Elsevier 2007.
• 9. Sharma SD. Hepatitis c virus: Molecular biology & current therapeutic options. Indian Journal of Medical Research. 2010;131(1):17-34.
• 10. Suzuki T, Aizaki H, Murakami K, Shoji I, Wakita T. Molecular biology of hepatitis C virus. Journal of Gastroenterology. 2007;42(6):411-23.
• 11. Negro F, Alberti A. The global health burden of hepatitis C virus infection. Liver international : official journal of the International Association for the Study of the Liver. [Editorial Introductory Research Support, Non-U.S. Gov't]. 2011 Jul;31 Suppl 2:1-3.
• 12. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. [Review]. 2011 Feb;17(2):107-15.
• 13. Alter MJ. Epidemiology of hepatitis C virus infection. World journal of gastroenterology : WJG. [Review]. 2007 May 7;13(17):2436-41.
• 14. Santantonio T, Wiegand J, Tilman Gerlach J. Acute hepatitis C: Current status and remaining challenges. Journal of hepatology. 2008;49(4):625-33.
• 15. Modi AA, Liang TJ. Hepatitis C: A clinical review. Oral Diseases. 2008;14(1):10-4.
• 16. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. International Journal of Medical Sciences. 2006;3(2):47-52.
• 17. Kamal SM. Acute hepatitis C: A systematic review. American Journal of Gastroenterology. 2008;103(5):1283-97.
• 18. Missiha SB, Ostrowski M, Heathcote EJ. Disease Progression in Chronic Hepatitis C: Modifiable and Nonmodifiable Factors. Gastroenterology. 2008;134(6):1699-714.
• 19. Bostan N, Mahmood T. An overview about hepatitis C: A devastating virus. Critical Reviews in Microbiology. 2010;36(2):91-133.
• 20. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36(5 I):S35-S46.
• 21. SIGN. Management of Hepatitis C: a national clinical guideline: Scottish Intercollegiate Guidelines Network2006 December 2006.
• 22. Ray R. Progress toward development of a hepatitis C vaccine with broad shoulders. Science Translational Medicine. 2011;3(94).
• 23. Butt AA, Kanwal F. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients. Clinical Infectious Diseases. 2012;54(1):96-104.
• 24. Shiffman ML, Esteban R. Triple therapy for HCV genotype 1 infection: Telaprevir or boceprevir? Liver International. 2012;32(SUPPL. 1):54-60.
• 25. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012 May 1, 2012;61(Suppl 1):i36-i46.
• 26. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis C: A cost-effectiveness analysis. Annals of Internal Medicine. 2012;156(4):279-90.
• 27. Cooper CL, Druyts E, Thorlund K, Nachega JB, El Khoury AC, O'Regan C, et al. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. Therapeutics and clinical risk management. 2012 2012;8:105-30.